Pathogenetic analysis of cognitive impairment in comorbid patients as a basis for rational therapy

Announcement:

We present to your attention a report from the Bekhterev Readings from Professor of the Department of Nervous Diseases of the S.M. Kirov Military Medical Academy, Vice President of the Eurasian Association of Neurologists Sergei Anatolyevich Zhivolupov on cognitive impairment as a multifactorial problem requiring a pathogenetic approach.

After watching this video lecture, you will learn:

• Why are cognitive impairments not a death sentence, but an alarm signal, especially in patients with arterial hypertension and other forms of polymorbidity?
• What factors accelerate cognitive decline, from vascular and metabolic to infectious (including post-COVID syndrome)?
• Why is early diagnosis the key to reversibility? At the stage of mild and moderate disorders, it is still possible to influence the prognosis.
• What neuroimaging and clinical data allow for pathogenetic reconstruction and differential diagnosis?
• How does vascular cognitive dysfunction differ from neurodegenerative cognitive dysfunction (for example, in Alzheimer's disease) - and why do we most often encounter mixed forms?

Particular attention is paid to differential diagnostics: from vitamin deficiency and hypothyroidism to iatrogenic causes and rare forms (for example, primary angiitis of the central nervous system). The expert also explains why the analysis of the contour of cognitive impairment (memory, attention, executive functions, gnosis, praxis) is more important than just memory assessment.

The report examines in detail the MEMO study: the effectiveness of the drug Mexidol in patients with chronic cerebral ischemia and hypertension. The drug is included in current clinical guidelines for ischemic stroke and cognitive impairment in the elderly.

Watch the report to:

• Learn to conduct a pathogenetic analysis of cognitive impairment;
• Understand how to build therapy not based on symptoms, but on the mechanism;
• Find out why Mexidol is an evidence-based choice

The video material is a must-see for neurologists, therapists, general practitioners and anyone who treats patients with hypertension, vascular and polymorbid diseases.